UBS O'Connor’s Vanda Pharmaceuticals VNDA Stock Holding History

UBS O'Connor’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-137,280	Closed	-$2.31M	–	371
2018 Q1	$2.31M	Buy	+137,280	New	+$2.3M	0.04%	167

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS O'Connor's VNDA Position: Q2 2018 in Review

UBS O'Connor sold out of Vanda Pharmaceuticals (VNDA) in Q2 2018, closing a stake of 137,280 shares — an estimated $2.31M sold.

UBS O'Connor first reported a position in VNDA in Q1 2018 and held it in 1 quarter. The position peaked at $2.31M in Q1 2018. 135 funds tracked by Wall St. Rank hold VNDA as of Q2 2018.

UBS O'Connor reported no remaining Vanda Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
UBS O'Connor sold 137,280 Vanda Pharmaceuticals shares in Q2 2018, an estimated $2.31M.
UBS O'Connor first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 1 quarter.
UBS O'Connor's Vanda Pharmaceuticals position peaked at $2.31M in Q1 2018.
135 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2018.

Based on UBS O'Connor's 13F filing for Q2 2018, filed 14 Aug 2018.